Literature DB >> 12681522

Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine.

S Stevens Negus1, Michael R Brandt, Michael B Gatch, Nancy K Mello.   

Abstract

Recent studies have reported differences in the receptor mechanisms and intrinsic efficacies of heroin and its metabolites 6-acetylmorphine and morphine in rodents. The present study examined the generality of these findings to rhesus monkeys using two behavioral procedures. In an assay of schedule-controlled behavior, response rates were recorded under a fixed-ratio 30 schedule of food presentation. In an assay of thermal nociception, tail-withdrawal latencies were measured from warm water (42-58 degrees C). Heroin, 6-acetylmorphine and morphine produced dose-dependent rate-decreasing and antinociceptive effects. Antagonism studies were conducted with the competitive mu-selective antagonist quadazocine, the competitive delta-selective antagonist naltrindole, and the irreversible mu-selective antagonist beta-funaltrexamine (beta-FNA). Quadazocine dose-dependently antagonized the effects of all three opioids. Quadazocine pA2 values were similar across drugs and assays (7.4-7.8) and similar to quadazocine pA2 values for antagonism of other mu agonists. In contrast, naltrindole did not alter the effects of any of the opioids. beta-FNA antagonized the rate-decreasing and antinociceptive effects of heroin and morphine. Dose-effect data for heroin- and morphine-induced antinociception alone and after beta-FNA treatment were used to estimate in vivo apparent efficacy values (tau). Tau values (95% confidence limits) were 8.1 (6.9-9.6) for heroin and 2.6 (2.5-2.9) for morphine, but this difference is relatively small. These results suggest that the rate-decreasing and antinociceptive effects of heroin, 6-acetylmorphine and morphine are mediated by pharmacologically similar populations of mu opioid receptors in rhesus monkeys. The in vivo apparent efficacy of heroin at mu receptors was similar to or only slightly greater than that of morphine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12681522     DOI: 10.1016/s0376-8716(02)00331-9

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  9 in total

1.  Vaccine blunts fentanyl potency in male rhesus monkeys.

Authors:  Rebekah D Tenney; Steven Blake; Paul T Bremer; Bin Zhou; Candy S Hwang; Justin L Poklis; Kim D Janda; Matthew L Banks
Journal:  Neuropharmacology       Date:  2019-07-29       Impact factor: 5.250

Review 2.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

3.  Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.

Authors:  Sandra D Comer; Ellen A Walker; Eric D Collins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  Role of µ-opioid receptor reserve and µ-agonist efficacy as determinants of the effects of µ-agonists on intracranial self-stimulation in rats.

Authors:  Ahmad A Altarifi; Laurence L Miller; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2012-10       Impact factor: 2.293

5.  Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.

Authors:  Jeremy C Cornelissen; Samuel Obeng; Kenner C Rice; Yan Zhang; S Stevens Negus; Matthew L Banks
Journal:  J Pharmacol Exp Ther       Date:  2018-01-12       Impact factor: 4.030

6.  Modulation of Fas receptor proteins and dynamin during opiate addiction and induction of opiate withdrawal in rat brain.

Authors:  M Julia García-Fuster; Marcel Ferrer-Alcón; Antonio Miralles; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-03       Impact factor: 3.000

7.  Development of a Clinically Viable Heroin Vaccine.

Authors:  Paul T Bremer; Joel E Schlosburg; Matthew L Banks; Floyd F Steele; Bin Zhou; Justin L Poklis; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-06-20       Impact factor: 15.419

Review 8.  Translational value of non-human primates in opioid research.

Authors:  Huiping Ding; Mei-Chuan Ko
Journal:  Exp Neurol       Date:  2021-01-14       Impact factor: 5.330

Review 9.  The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies.

Authors:  Ying Han; Wei Yan; Yongbo Zheng; Muhammad Zahid Khan; Kai Yuan; Lin Lu
Journal:  Transl Psychiatry       Date:  2019-11-11       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.